Combination therapies with epothilones and carboplatin

• US 20050215604A1
• Filed: 03/23/2005
• Published: 09/29/2005
• Est. Priority Date: 03/26/2004
• Status: Abandoned Application

• Current Assignee: Kosan Biosciences, Inc. (Bristol-Myers Squibb Company)
• Original Assignee: Kosan Biosciences, Inc. (Bristol-Myers Squibb Company)
• Inventors: Johnson, Robert G. Jr., Zhou, Yiqing
• Application Number:
  US11/088,534
• Publication Number:
  US 20050215604A1
• Time in Patent Office: Days
• US Class Current: 514/365
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A combination therapy of an epothilone and carboplatin is effective for treating tumors.

Claims

1. A method for treating diseases characterized by cellular hyperproliferation, comprising administering to a patient in need of such treatment a combination of an epothilone and carboplatin.

2. The method of claim 1, wherein the epothilone is epothilone D.

3. The method of claim 2, wherein the disease is cancer.

4. The method of claim 3, wherein the disease is non-small cell lung cancer.

5. The method of claim 1, wherein the disease is cancer.

6. The method of claim 5, wherein the disease is non-small cell lung cancer.

7. The method of claim 1, wherein the patient is first treated with the epothilone, and subsequently is treated with carboplatin.

8. The method of claim 1, wherein the patient is treated simultaneously with the epothilone and with carboplatin.

9. A pharmaceutical composition comprising an epothilone together with carboplatin and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 9, wherein the epothilone is epothilone D.

11. A kit comprising a first pharmaceutical composition comprising an epothilone and a second pharmaceutical composition comprising carboplatin.

12. The kit of claim 11, wherein the epothilone is epothilone D.